Role of biologics in severe eosinophilic asthma – focus on reslizumab
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia&r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-07-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/role-of-biologics-in-severe-eosinophilic-asthma-ndash-focus-on-reslizu-peer-reviewed-article-TCRM |
| _version_ | 1818956668104343552 |
|---|---|
| author | Pelaia G Vatrella A Busceti MT Gallelli L Preianò M Lombardo N Terracciano R Maselli R |
| author_facet | Pelaia G Vatrella A Busceti MT Gallelli L Preianò M Lombardo N Terracciano R Maselli R |
| author_sort | Pelaia G |
| collection | DOAJ |
| description | Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of Medicine and Surgery, Section of Respiratory Diseases, University of Salerno, Salerno, Italy; 3Department of Health Science, University “Magna Græcia” of Catanzaro, Catanzaro, Italy Abstract: Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. Keywords: IL-5, eosinophilic asthma, reslizumab, chronic obstructive pulmonary disease, MAPK, Janus kinases |
| first_indexed | 2024-12-20T10:57:37Z |
| format | Article |
| id | doaj.art-d9f2fcc33342414c8eeda05deb43dddb |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-20T10:57:37Z |
| publishDate | 2016-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-d9f2fcc33342414c8eeda05deb43dddb2022-12-21T19:43:07ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2016-07-012016Issue 11075108227730Role of biologics in severe eosinophilic asthma – focus on reslizumabPelaia GVatrella ABusceti MTGallelli LPreianò MLombardo NTerracciano RMaselli RGirolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of Medicine and Surgery, Section of Respiratory Diseases, University of Salerno, Salerno, Italy; 3Department of Health Science, University “Magna Græcia” of Catanzaro, Catanzaro, Italy Abstract: Within the context of the heterogeneous phenotypic stratification of asthmatic population, many patients are characterized by moderate-to-severe eosinophilic asthma, not adequately controlled by relatively high dosages of inhaled and even oral corticosteroids. Therefore, these subjects can obtain significant therapeutic benefits by additional biologic treatments targeting interleukin-5 (IL-5), given the key pathogenic role played by this cytokine in maturation, activation, proliferation, and survival of eosinophils. In particular, reslizumab is a humanized anti-IL-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids. These important therapeutic effects of reslizumab, demonstrated by several controlled clinical trials, have led to the recent approval by US Food and Drug Administration of its use, together with other antiasthma medications, for the maintenance treatment of patients suffering from severe uncontrolled asthma. Keywords: IL-5, eosinophilic asthma, reslizumab, chronic obstructive pulmonary disease, MAPK, Janus kinaseshttps://www.dovepress.com/role-of-biologics-in-severe-eosinophilic-asthma-ndash-focus-on-reslizu-peer-reviewed-article-TCRMIL-5eosinophilic asthmareslizumab |
| spellingShingle | Pelaia G Vatrella A Busceti MT Gallelli L Preianò M Lombardo N Terracciano R Maselli R Role of biologics in severe eosinophilic asthma – focus on reslizumab Therapeutics and Clinical Risk Management IL-5 eosinophilic asthma reslizumab |
| title | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
| title_full | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
| title_fullStr | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
| title_full_unstemmed | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
| title_short | Role of biologics in severe eosinophilic asthma – focus on reslizumab |
| title_sort | role of biologics in severe eosinophilic asthma ndash focus on reslizumab |
| topic | IL-5 eosinophilic asthma reslizumab |
| url | https://www.dovepress.com/role-of-biologics-in-severe-eosinophilic-asthma-ndash-focus-on-reslizu-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT pelaiag roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT vatrellaa roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT buscetimt roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT gallellil roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT preianogravem roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT lombardon roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT terraccianor roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab AT masellir roleofbiologicsinsevereeosinophilicasthmandashfocusonreslizumab |